Endometrial pathology in breast cancer patients: Effect of different treatments on ultrasonographic, hysteroscopic and histological findings

Le Donne,Maria; Alibrandi,Angela; Ciancimino,Leonarda; Azzerboni,Andrea; Chiofalo,Benito; Triolo,Onofrio

doi:10.3892/ol.2013.1156

Endometrial pathology in breast cancer patients: Effect of different treatments on ultrasonographic, hysteroscopic and histological findings

Authors:
- Maria Le Donne
- Angela Alibrandi
- Leonarda Ciancimino
- Andrea Azzerboni
- Benito Chiofalo
- Onofrio Triolo
View Affiliations

Affiliations: Department of Gynecological, Obstetrical Sciences and Reproductive Medicine, University of Messina, Messina, Italy, Department of Economical, Business and Environmental Sciences and Quantitative Methods, University of Messina, Messina, Italy
Published online on: January 28, 2013 https://doi.org/10.3892/ol.2013.1156
Pages: 1305-1310

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer patients have an increased risk of endometrial pathology. To investigate whether the incidence of endometrial abnormalities and their clinicopathological features were affected by receiving tamoxifen (TAM), non‑steroidal aromatase inhibitors (AIs) or no treatment (NT), 333 peri/postmenopausal breast cancer patients, who were referred to the Department of Gynecological, Obstetrical Sciences and Reproductive Medicine for gynecological assessment, were reviewed retrospectively. Transvaginal ultrasonographic (TVUS), hysteroscopic and histological findings were investigated. Endometrial histological findings included: atrophy in 61, 94.3 and 55.6% of cases in the TAM, AIs and NT groups, respectively; polyps in 30.9, 31.4 and 42.2% of cases in the TAM, AIs and NT groups, respectively; hyperplasia in 3% of patients in the TAM group and 11.1% of patients in the NT group; and cancer in 3.8% of cases in the TAM group and 11.1% of cases in the NT group. There was a significant correlation between the duration of TAM treatment and the severity of endometrial pathology. In all groups, there was a significant correlation between hysteroscopic and histological findings with regard to the diagnosis of endometrial atrophy, polyps, hyperplasia and cancer (P<0.001). In conclusion, these data revealed that there was a higher incidence of endometrial pathology in the NT group compared with the TAM group, which was significant for endometrial hyperplasia and cancer. The chance of developing high-risk histological subtypes of endometrial cancer was independent of TAM use. Lastly, although there was no significant difference in recurrent vaginal bleeding and mean endometrial thickness between the TAM and AIs groups, patients receiving AIs did not exhibit hyperplastic, dysplastic or neoplastic changes in the endometrium. This study indicates that breast cancer patients require screening for endometrial pathology; TVUS alone is useful in asymptomatic patients, however, in patients where the endometrial line is irregular or its thickness is >3 mm, hysteroscopy with directed biopsy is the appropriate diagnostic method.

View Figures

View References

1	No authors listed. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Early Breast Cancer Trialists' Collaborative Group. Lancet. 339:1–15. 1992.
2	Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 86:527–537. 1994. View Article : Google Scholar
3	Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer: occurence of new primary cancers. Lancet. 1:117–120. 1989. View Article : Google Scholar : PubMed/NCBI
4	Fugh-Berman A and Epstein S: Tamoxifen: disease prevention or disease substitution? Lancet. 340:1143–1145. 1992. View Article : Google Scholar : PubMed/NCBI
5	Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T and Wilking N: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group J Natl Cancer Inst. 87:645–651. 1995. View Article : Google Scholar : PubMed/NCBI
6	van Leeuwen FE, Benraadt J, Coebergh JW, et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 343:448–452. 1994.PubMed/NCBI
7	Jones ME, van Leeuwen FE, Hoogendoorn WE, et al: Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res. 14:R912012. View Article : Google Scholar : PubMed/NCBI
8	Bergman L, Beelen ML, Gallee MP, et al: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group Assessment of Liver and Endometrial cancer risk following Tamoxifen. Lancet. 356:881–887. 2000.PubMed/NCBI
9	Le Donne M, Lentini M, De Meo L, Benedetto V and Mesiti M: Uterine pathologies in patients undergoing tamoxifen therapy for breast cancer: ultrasonographic, hysteroscopic and histological findings. Eur J Gynaecol Oncol. 26:623–626. 2005.
10	Cohen I, Altaras MM, Shapira J, Tepper R, Rosen DJ, Cordoba M, et al: Time-depedent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. Int J Gynecol Pathol. 15:152–157. 1996. View Article : Google Scholar
11	Dowsett M, Jones A, Johnston SR, et al: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res. 1:1511–1515. 1995.PubMed/NCBI
12	Geisler J, King N, Dowsett M, et al: Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer. 74:1286–1291. 1996. View Article : Google Scholar
13	Howell A, Cuzick J, Baum M, et al ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 365:60–62. 2005.
14	Boccardo F, Rubagotti A, Puntoni M, et al: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 23:5138–5147. 2005. View Article : Google Scholar
15	Duffy S, Jackson TL, Lansdown M, et al ATAC Trialists' Group: The ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy. Hum Reprod. 20:294–301. 2005.
16	Gerber B, Krause A, Reimer T, et al: Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. Clin Cancer Res. 12:1245–1250. 2006. View Article : Google Scholar
17	Valenzano Menada M, Costantini S, Moioli M, et al: Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole. Breast. 17:631–636. 2008.
18	Markovitch O, Tepper R, Fishman A, et al: Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients. Breast Cancer Res Treat. 101:185–190. 2007. View Article : Google Scholar
19	Morales L, Timmerman D, Neven P, et al: Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol. 16:70–74. 2005. View Article : Google Scholar
20	Cohen I, Beyth Y, Azaria R, Flex D, Figer A and Tepper R: Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients. BJOG. 107:1083–1087. 2000. View Article : Google Scholar
21	Liedman R, Lindahl B, Andolf E, Willen R, Ingvar C and Ranstam J: Disaccordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treated with tamoxifen. Anticancer Res. 20:4889–4891. 2000.
22	Fung MF, Reid A, Faught W, et al: Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol. 91:154–159. 2003. View Article : Google Scholar : PubMed/NCBI
23	Bertelli GF, Valenzano M, Costantini S, et al: Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen. Gynecol Oncol. 78:275–277. 2000. View Article : Google Scholar : PubMed/NCBI
24	Develioğlu OH, Omak M, Bilgin T, Esmer A and Tüfekçi M: The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow. Gynecol Oncol. 93:328–335. 2004.PubMed/NCBI
25	Giorda G, Crivellari D, Veronesi A, Perin T, Campagnutta E, Carbone A and Scarabelli C: Comparison of ultrasonography, hysteroscopy, and biopsy in the diagnosis of endometrial lesions in postmenopausal tamoxifen-treated patients. Acta Obstet Gynecol Scand. 81:975–980. 2002. View Article : Google Scholar : PubMed/NCBI
26	Hann LE, Giess CS, Bach AM, Tao Y, Baum HJ and Barakat RR: Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. AJR Am J Roentgenol. 168:657–661. 1997. View Article : Google Scholar : PubMed/NCBI
27	No authors listed. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 351:1451–1467. 1998.
28	Mourits MJ, Van der Zee AG, Willemse PH, Ten Hoor KA, Hollema H and De Vries EG: Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol. 73:21–26. 1999. View Article : Google Scholar
29	Neven P and Vernaeve H: Guidelines for monitoring patients taking tamoxifen treatment. Drug Saf. 22:1–11. 2000. View Article : Google Scholar : PubMed/NCBI
30	Jordan VC and Assikis VJ: Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res. 1:467–472. 1995.PubMed/NCBI
31	Dallenbach-Hellweg G and Hahn U: Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens. Int J Gynecol Pathol. 14:7–15. 1995. View Article : Google Scholar : PubMed/NCBI
32	Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR and Boyd J: Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol. 92:719–725. 2004. View Article : Google Scholar : PubMed/NCBI
33	Wilder JL, Shajahan S, Khattar NH, et al: Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study. Gynecol Oncol. 92:553–558. 2004. View Article : Google Scholar
34	Slomovitz BM, Sun CC, Ramirez PT, Bodurka DC, Diaz P and Lu KH: Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol. 104:255–260. 2004. View Article : Google Scholar : PubMed/NCBI
35	Fles R, Hoogendoorn WE, Platteel I, et al: Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure. Genes Chromosomes Cancer. 49:699–710. 2010. View Article : Google Scholar : PubMed/NCBI
36	Schaapveld M, Visser O, Louwman MJ, et al: Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol. 26:1239–1246. 2008. View Article : Google Scholar : PubMed/NCBI
37	Kirova YM, De Rycke Y, Gambotti L, Pierga JY, Asselain B and Fourquet A; Institut Curie Breast Cancer Study Group: Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer. 98:870–874. 2008. View Article : Google Scholar : PubMed/NCBI
38	Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B and Fourquet A: Risk of second malignancies after adjuvant radio-therapy for breast cancer: a large-scale, single institution review. Int J Radiat Oncol Biol Phys. 68:359–363. 2007. View Article : Google Scholar : PubMed/NCBI
39	Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 23:619–629. 2005. View Article : Google Scholar
40	Machado F, Rodríguez JR, León JP, Rodríguez JR, Parrilla JJ and Abad L: Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. Eur J Gynaecol Oncol. 26:257–265. 2005.PubMed/NCBI